Editorial: moving from the clinic towards population hepatology
- PMID: 36821757
- DOI: 10.1111/apt.17394
Editorial: moving from the clinic towards population hepatology
Comment in
-
Editorial: moving from the clinic towards population hepatology-authors' reply.Aliment Pharmacol Ther. 2023 Mar;57(6):728. doi: 10.1111/apt.17400. Aliment Pharmacol Ther. 2023. PMID: 36821746 No abstract available.
Comment on
-
Improved prediction of 10-year risk of severe liver disease in the general population using commonly available biomarkers.Aliment Pharmacol Ther. 2023 Feb;57(4):418-425. doi: 10.1111/apt.17374. Epub 2022 Dec 25. Aliment Pharmacol Ther. 2023. PMID: 36566508 Free PMC article.
References
REFERENCES
-
- Hagström H, Yan J, Talbäck M, Andreasson A, Walldius G, Bottai M, et al. Improved prediction of 10-year risk of severe liver disease in the general population using commonly available biomarkers. Aliment Pharmacol Ther. 2023;57(4):418-25. https://doi.org/10.1111/apt.17374
-
- Hagström H, Adams LA, Allen AM, Byrne CD, Chang Y, Grønbaek H, et al. Administrative coding in electronic health care record-based research of NAFLD: an expert panel consensus statement. Hepatology. 2021;74:474-82.
-
- Papatheodoridi M, Hiriart JB, Lupsor-Platon M, Bronte F, Boursier J, Elshaarawy O, et al. Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease. J Hepatol. 2021;74:1109-16.
-
- Shearer JE, Jones R, Parker R, Ferguson J, Rowe IA. The natural history of advanced chronic liver disease defined by transient elastography. Clin Gastroenterol Hepatol. 2022. https://doi.org/10.1016/j.cgh.2022.03.015
-
- Roskilly A, Hicks A, Taylor EJ, Jones R, Parker R, Rowe IA. Fibrosis progression rate in a systematic review of placebo-treated nonalcoholic steatohepatitis. Liver Int. 2020;41:982-95. https://doi.org/10.1111/liv.14749